Streetbeat News

Price Targets

MGA

Morgan Stanley has downgraded Magna International from Overweight to Equal-Weight and reduced its price target from $55 to $43.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:58 pm

LAD

Morgan Stanley analyst Adam Jonas has upgraded Lithia Motors (NYSE:LAD) from Underweight to Equal-Weight and increased the price target from $225 to $310.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:56 pm

PRGS

Progress Software shares are trading higher due to Oppenheimer's increased price target from $66 to $70, alongside strong Q3 earnings and guidance.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:49 pm

GPI

Morgan Stanley has upgraded Group 1 Automotive (NYSE:GPI) from Equal-Weight to Overweight, raising the price target from $285 to $430.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:48 pm

NOW

The options market shows a bullish sentiment towards ServiceNow (NYSE:NOW), with 64% of traders favoring calls over puts. The price target is between $600 and $920, with significant trading activity in this range. Despite a recent 3.35% price drop, the consensus target price remains at $900. An analyst from Needham has lowered the rating to Buy with a $900 target.

Portfolio Pulse from Benzinga Insights

September 25, 2024 | 1:46 pm

ABG

Morgan Stanley has upgraded Asbury Automotive Group (NYSE:ABG) from Underweight to Equal-Weight and increased the price target from $190 to $240.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:46 pm

IMO

Scotiabank has downgraded Imperial Oil (AMEX:IMO) from Sector Outperform to Sector Perform, while maintaining the price target at $110.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:33 pm

NOV

Wells Fargo analyst Roger Read has downgraded NOV from Equal-Weight to Underweight and reduced the price target from $20 to $16.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:25 pm

BKR

Wells Fargo analyst Roger Read has upgraded Baker Hughes (NASDAQ:BKR) from Equal-Weight to Overweight and increased the price target from $40 to $42.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:23 pm

SMMT

Stifel analyst Bradley Canino has maintained a Buy rating on Summit Therapeutics and raised the price target from $25 to $40.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:23 pm